kidney drug approved from phase 2, page-5

re: trademark secured The RCC market is worth about $180,000,000. Modest by big pharma standards, but still pretty big compared to Solbec market cap
Here is a deal Bayer signed with Onyx a few years back to secure a share of their kidney drug. Bayer paid 40M up front.
"Our collaboration agreement with Bayer calls for creditable milestone-based payments. These amounts are interest-free and will be repayable to Bayer from a portion of any of our future profits and royalties. We received a $5.0 million in the third quarter of 2002 upon initiation of Phase II clinical studies and $15.0 million in the fourth quarter of 2003 based upon the initiation of a Phase III study. Based on the July 2005 NDA filing, we received the third milestone advance for $10.0 million in the third quarter of 2005. In addition, in January 2006, we received the final $10.0 million milestone advance as a result of the U.S. approval of Nexavar in December 2005. We received a total of $40.0 million of milestone advances from Bayer in connection with the development and approval of Nexavar. "
http://biz.yahoo.com/e/060809/onxx10-q.html
"Given the modest market opportunity in renal cell carcinoma ($184M in estimated 2010 sales), "
Modest by Pfizers and Genentech standard perhaps with market caps around 70 Billion US$
http://www.wrhambrecht.com/research/biotech/ir/index.html
Good luck to Solbec holders